Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan D Finn

Showing results (1-10 of 26) with videos related to

Pageof 3
Sort By:
Idrugs : the Investigational Drugs Journal|December 23, 2003
American Society of Gene Therapy - Fifth Annual MeetingJonathan D Finn
BMC Molecular Biology|May 13, 2005
Investigation of factors responsible for cell line cytoplasmic expression differencesJonathan D Finn, Tabitha Wong, Pieter R Cullis
Molecular Therapy : the Journal of the American Society of Gene Therapy|July 9, 2009
Strategies to modulate immune responses: a new frontier for gene therapyValder R Arruda, Patricia Favaro, Jonathan D Finn
Frontiers in Immunology|September 16, 2024
Unlocking the potential of iPSC-derived immune cells: engineering iNK and iT cells for cutting-edge immunotherapyMinggang Fang, Alexander Allen, Chong Luo, et al.
Journal of Extracellular Vesicles|October 10, 2022
Transfection reagent artefact likely accounts for some reports of extracellular vesicle functionRussell E McConnell, Madeleine Youniss, Bhargavee Gnanasambandam, et al.
Molecular Therapy. Methods & Clinical Development|June 4, 2020
Timing of Intensive Immunosuppression Impacts Risk of Transgene Antibodies after AAV Gene Therapy in Nonhuman PrimatesBenjamin J Samelson-Jones, Jonathan D Finn, Patricia Favaro, et al.
JCI Insight|June 21, 2019
Hyperactivity of factor IX Padua (R338L) depends on factor VIIIa cofactor activityBenjamin J Samelson-Jones, Jonathan D Finn, Lindsey A George, et al.
Human Gene Therapy|December 4, 2010
Safety of liver gene transfer following peripheral intravascular delivery of adeno-associated virus (AAV)-5 and AAV-6 in a large animal modelPatricia Favaro, Jonathan D Finn, Joshua I Siner, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|November 12, 2009
Proteasome inhibitors decrease AAV2 capsid derived peptide epitope presentation on MHC class I following transductionJonathan D Finn, Daniel Hui, Harre D Downey, et al.
Human Gene Therapy|November 4, 2016
Empty Capsids and Macrophage Inhibition/Depletion Increase rAAV Transgene Expression in Joints of Both Healthy and Arthritic MiceCaroline J Aalbers, Niels Broekstra, Mariska van Geldorp, et al.
Pageof 3

Showing results (1-10 of 26) with videos related to

Sort By:
Pageof 3
Idrugs : the Investigational Drugs Journal|December 23, 2003
American Society of Gene Therapy - Fifth Annual MeetingJonathan D Finn
BMC Molecular Biology|May 13, 2005
Investigation of factors responsible for cell line cytoplasmic expression differencesJonathan D Finn, Tabitha Wong, Pieter R Cullis
Molecular Therapy : the Journal of the American Society of Gene Therapy|July 9, 2009
Strategies to modulate immune responses: a new frontier for gene therapyValder R Arruda, Patricia Favaro, Jonathan D Finn
Frontiers in Immunology|September 16, 2024
Unlocking the potential of iPSC-derived immune cells: engineering iNK and iT cells for cutting-edge immunotherapyMinggang Fang, Alexander Allen, Chong Luo, et al.
Journal of Extracellular Vesicles|October 10, 2022
Transfection reagent artefact likely accounts for some reports of extracellular vesicle functionRussell E McConnell, Madeleine Youniss, Bhargavee Gnanasambandam, et al.
Molecular Therapy. Methods & Clinical Development|June 4, 2020
Timing of Intensive Immunosuppression Impacts Risk of Transgene Antibodies after AAV Gene Therapy in Nonhuman PrimatesBenjamin J Samelson-Jones, Jonathan D Finn, Patricia Favaro, et al.
JCI Insight|June 21, 2019
Hyperactivity of factor IX Padua (R338L) depends on factor VIIIa cofactor activityBenjamin J Samelson-Jones, Jonathan D Finn, Lindsey A George, et al.
Human Gene Therapy|December 4, 2010
Safety of liver gene transfer following peripheral intravascular delivery of adeno-associated virus (AAV)-5 and AAV-6 in a large animal modelPatricia Favaro, Jonathan D Finn, Joshua I Siner, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|November 12, 2009
Proteasome inhibitors decrease AAV2 capsid derived peptide epitope presentation on MHC class I following transductionJonathan D Finn, Daniel Hui, Harre D Downey, et al.
Human Gene Therapy|November 4, 2016
Empty Capsids and Macrophage Inhibition/Depletion Increase rAAV Transgene Expression in Joints of Both Healthy and Arthritic MiceCaroline J Aalbers, Niels Broekstra, Mariska van Geldorp, et al.
Pageof 3